Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907290 | 0.87 | GRM5 (0.77) | GRM5APP | |
| SCHEMBL13907283 | 0.84 | GRM5 (0.70) | GRM5ATM | |
| SCHEMBL13907291 | 0.79 | GRM5 (0.65) | GRM5ATM | |
| SCHEMBL401836 | 0.78 | GRM5 (0.64) | GRM5APP | |
| SCHEMBL31673222 | 0.78 | GRM5 (0.64) | GRM5APP | |
| SCHEMBL13907284 | 0.78 | GRM5 (0.63) | GRM5ATM | |
| Diphenylacetylene SCHEMBL29188592 | 0.78 | APP (1.00) | GRM5APPMAPT | |
| Diphenylacetylene SCHEMBL960609 | 0.78 | APP (1.00) | GRM5APPMAPT | |
| Diphenylacetylene SCHEMBL68254 | 0.78 | APP (1.00) | GRM5APPMAPT | |
| SCHEMBL2520701 | 0.76 | GRM5 (0.62) | GRM5APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9784740-B2 | Positive allosteric modulators and silent allosteric modulators of the Mu opioid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150338404-A1 | POSITIVE ALLOSTERIC MODULATORS AND SILENT ALLOSTERIC MODULATORS OF THE Mu OPIOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-7462619-B2 | Pyridazine, pyrimidine and pyrazine ethyne compounds | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462619-B2 | Pyridazine, pyrimidine and pyrazine ethyne compounds | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20050245542-A1 | Pyridazine, pyrimidine and pyrazine ethyne compounds | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245542-A1 | Pyridazine, pyrimidine and pyrazine ethyne compounds | P2RX5, P2RY12, P2RY4 | GRM5 52/4885APP 2144/4885ATM 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.